Abstract

FMC Corp will report second-quarter results on July 29, 2026 Post-Mkt; this preview summarizes consensus forecasts, last quarter’s actuals, and the balance of institutional views across crop protection demand, pricing, and inventory normalization.

Market Forecast

Consensus for the current quarter points to revenue of 0.91 billion US dollars, down 9.17% year over year, EBIT of 0.10 billion US dollars, and adjusted EPS of 0.22, implying a 63.91% decline year over year. Forecast gross margin and net margin are not provided by the market screens we collected. The company’s core franchise is expected to stabilize with gradual recovery in Latin America and steady pricing in selective herbicide and insecticide actives, while channel inventories continue to weigh in Europe. The most promising pocket is Plant Health, where resilient demand and broadening distribution underpin mid-single-digit growth off a roughly 0.05 billion US dollars quarterly base; year-over-year details are not disclosed in the forecasts.

Last Quarter Review

FMC Corp posted revenue of 0.76 billion US dollars, a gross profit margin of 32.51%, a GAAP net loss attributable to the parent of 0.28 billion US dollars, a net margin of -37.08%, and adjusted EPS of -0.23, with revenue down 3.66% year over year and EPS down 227.78% year over year. The quarter’s notable feature was tighter operating discipline that delivered an EBIT outperformance versus prior estimates even as volumes stayed soft. Main business highlights showed insecticides at 0.34 billion US dollars, herbicides at 0.31 billion US dollars, fungicides at 0.06 billion US dollars, and plant health at 0.05 billion US dollars; year-over-year growth by segment was not disclosed.

Current Quarter Outlook

Main business momentum

The core crop protection portfolio, anchored by insecticides and herbicides, will likely see mixed dynamics this quarter. Distributors in Europe and North America remain focused on working down inventories, which limits replenishment orders even as application intensity steadies in key crops. In Latin America, order patterns are improving from a low base, but the pace of recovery is constrained by growers’ cash discipline and staggered procurement. Price realization appears stable on differentiated actives, which should help protect dollar margins, yet mix and volume drag are still expected to cap gross margin expansion relative to last year’s levels.

Most promising business

Plant Health continues to be the most resilient category within the portfolio, benefiting from diversified end-market exposure and less direct competition from generics. With a roughly 0.05 billion US dollars quarterly revenue base, the segment’s growth is leveraged to distribution expansion and broader adoption of biologicals and biostimulants. Even modest year-over-year demand improvements can contribute a disproportionate share of incremental profit, given relatively attractive gross margins versus commodity herbicides; execution on new product launches and cross-selling into existing grower accounts will be key to sustaining momentum.

Key stock-price drivers this quarter

The stock is most sensitive to signs of channel normalization and updated volume guidance, which could either validate a trough narrative or signal an elongated recovery path. Any quantitative commentary on gross margin trajectory, including mix between proprietary actives and lower-margin products, will shape earnings quality perceptions. Finally, management’s outlook for free cash flow conversion and inventory management will be parsed closely, as cash generation provides flexibility for debt reduction and selective R&D and portfolio investments.

Analyst Opinions

Across recent institutional previews, the balance of views skews cautious. The prevailing argument centers on slow channel destocking in Europe and North America, muted volume rebound in row crops, and an earnings mix still heavily dependent on price over volume. Analysts emphasize that while EBIT is expected near 0.10 billion US dollars and adjusted EPS near 0.22, conviction in a rapid inflection remains limited until distributors accelerate reordering and growers’ budgets ease. In this framework, commentaries from well-followed brokerages highlight risk of continued year-over-year declines this quarter, with potential for a more meaningful recovery into the back half only if inventory levels normalize faster than currently assumed.